These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23594109)

  • 1. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
    Monami M; Genovese S; Mannucci E
    Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.
    Phung OJ; Schwartzman E; Allen RW; Engel SS; Rajpathak SN
    Diabet Med; 2013 Oct; 30(10):1160-71. PubMed ID: 23663156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
    Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Ahrén B; Dicembrini I; Mannucci E
    Diabetes Obes Metab; 2013 Feb; 15(2):112-20. PubMed ID: 22925682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials.
    Varvaki Rados D; Catani Pinto L; Reck Remonti L; Bauermann Leitão C; Gross JL
    PLoS Med; 2016 Apr; 13(4):e1001992. PubMed ID: 27071029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety of sulphonylurea: comment on the study by Monami et al.
    Du L; Chen Y; Shen J; Peng Y; Sun X
    Diabetes Obes Metab; 2014 Jul; 16(7):667-9. PubMed ID: 24320700
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
    Corley BT; Davenport C; Delaney L; Hatunic M; Smith D
    Diabet Med; 2011 Jul; 28(7):876-9. PubMed ID: 21204965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 17. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
    Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
    Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.